Lucija Tomljenovic, PhD
Lucija Tomljenovic holds a Ph.D in biochemistry and is currently a senior research fellow at the University of British Columbia School of Medicine in Vancouver, BC, Canada. Her research focuses on neuro- and immuno-toxicity of vaccines. In particular, Tomljenovic investigates mechanisms by which vaccines and their ingredients may induce neurological and autoimmune disease, with a particular focus on autism and related neurodevelopmental abnormalities. She also works on developing novel biomarker-based protocols which would enable determining whether some serious post-vaccination adverse events are causally linked to vaccinations. Her work has been featured in top-ranking medical journals including Lancet Infectious Diseases, Annals of Medicine, Journal of Internal Medicine, Journal of American Medical Association, Immunological Research, BMC Infectious Agents and Cancer, American Journal of Public Health, Journal of Law Medicine and Ethics, Current Pharmaceutical Design, Current Medicinal Chemistry, Vaccine and Lupus. Tomljenovic also serves as a peer reviewer for Vaccine, Journal of Inorganic Biochemistry, Lupus and Surgical Neurology International.
|
Lucija Tomljenovic, PhD, is a research scientist with the Neural Dynamics Research Group, Department of Ophthalmology and Visual Sciences at the University of British Colombia. She has extensive experience investigating the safety of vaccine adjuvants. The following are her contributions to the medical safety advocate’s arsenal:
Statement by Dr. Tomljenovic to Vermont House of Representatives regarding mandatory vaccines.
|
HPV Vaccine Safety and Efficacy Issues
|
Should the CDC and Merck's claims of efficacy and safety about Gardasil be accepted without scrutiny? Dr. Tomljenovic explores available data suggesting that there is no indication for this vaccine in the setting of Pap smear efficacy, that claims of vaccine efficacy are without an evidence base, and that risks including death and permanent disability have a known scientific mechanism. She asks, "Is it ethical to put young women at risk of death or a disabling autoimmune disease at a pre-adolescent age for a vaccine that has not yet prevented a single case of cervical cancer, a disease that may develop 20-30 years after exposure to HPV, when the same can be prevented with regular Pap screening which carries no risks?" ~ Vancouver, 2015
|
Aluminum in Vaccines
|
Vaccine Testing
|
Dr. Lucija Tomljenovic is an early career postdoctoral fellow. She was awarded a PhD in 2009 in Biochemistry, from the Comparative Genomics Centre at James Cook University in Townsville, Australia. In 2010, she joined the Neural Dynamics Research Group at the University of British Columbia (Chris Shaw’s lab) and is currently researching the neurotoxic effects of aluminum vaccine adjuvants. Tomljenovic has recently become an Associate Editor of the Journal of Alzheimer’s Disease. She values open-minded discussions on controversial topics and the pursuit of truth in research endeavors, wherever they may lead.
Additional Interviews with Dr. Tomljenovic
|
|